FDA Modernization Act 3.0 passed the House 466 days after introduction and awaits a vote in the Senate
Written by the Congressional Research Service [2]. 101 words.
FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
- Committees
- House Energy and Commerce Committee
- Policy area
- Health: 122 of 9,357 bills became law, 113th–118th (1.3%)
- Sponsor
- 7 of 178 bills enacted since 2013
- Text versions
- 3, from introduced in house to engrossed in house · 434 words
- Subjects
- Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationMedical researchResearch administration and funding
- Latest action
- Jul 21, 2026: Received in the Senate.
- Records
- Congress.gov · Bill text
Each bill appears once, under its strongest link. 1 in all.
Identical or companion · 1
- 119th S. 355 FDA Modernization Act 3.0 D · Passed one chamber